Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
PLOS ONE · 30.03.2023 · 18 (3) · e0283478
DOI: 10.1371/journal.pone.0283478 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 30.03.2023. Verfasst von Hui-Jeong Hwang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korean Society of Cardiology.
Abstract (Originalsprache)
Background
Twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may reduce drug adherence compared with once-daily dosing of NOACs in patients with atrial fibrillation (AF), thus worsening clinical outcomes. We evaluated adherence to apixaban and dabigatran requiring twice-daily dosing compared with edoxaban or rivaroxaban with a once-daily dosing regimen and the subsequent clinical outcomes in patients with AF.
Methods
Adherence to each NOAC and outcomes were compared between patients who were diagnosed with AF and initiated NOACs between 2016 and 2017 using Korean claims data. High adherence was defined as the proportion of days covered (PDC) of the index NOAC ≥80%. The clinical outcomes included stroke, acute myocardial infarction, death, and composite outcome.
Results
A total of 33,515 patients were analyzed (mean follow-up, 1.7 ± 1.3 years). The proportion of patients with high adherence to NOACs was 95%, which did not significantly differ according to the dosing regimen. The mean PDC for NOACs was as high as ~96%, which was the highest for apixaban users, intermediate for edoxaban or rivaroxaban users, and lowest for dabigatran users, regardless of the dosing regimen. Adverse outcomes in low adherence patients for each NOAC were higher than that of high adherence patients, regardless of the dosing frequency.
Conclusions
Adherence between once- and twice-daily dosing NOACs in patients with AF was high and similar among both dosing regimens. Patients with low NOAC adherence had poorer clinical outcomes, regardless of the dosing frequency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
- Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Korea.
ORCID-Profile: Il Suk Sohn
Förderung
- Korean Society of Cardiology
Zitieren
APA
Hwang, H. J., Sohn, I. S., Jin, E. S., & Bae, Y. J. (2023). Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?. PLOS ONE, 18(3), e0283478. https://doi.org/10.1371/journal.pone.0283478
Vancouver
Hwang HJ, Sohn IS, Jin ES, Bae YJ. Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?. PLOS ONE. 2023;18(3):e0283478. doi:10.1371/journal.pone.0283478
BibTeX
@article{Hwang2023,
author = {Hwang, Hui-Jeong and Sohn, Il Suk and Jin, Eun-Sun and Bae, Yoon-Jong},
title = {Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {3},
pages = {e0283478},
doi = {10.1371/journal.pone.0283478}
}
EUVIMED